Harvard Bioscience Inc.

12/30/2025 | Press release | Distributed by Public on 12/30/2025 19:46

Initial Statement of Beneficial Ownership (Form 3)

FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
Snider William
2. Date of Event Requiring Statement (Month/Day/Year)
12/17/2025
3. Issuer Name and Ticker or Trading Symbol
HARVARD BIOSCIENCE INC [HBIO]
(Last) (First) (Middle)
C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed (Month/Day/Year)
(Street)
HOLLISTON, MA 01746
6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Warrant (right to buy) (3) 12/17/2032 Common Stock 150,000 $0.5 I As manager(1)
Warrant (right to buy) (3) 12/17/2032 Common Stock 600,000 $0.5 I As manager(2)

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Snider William
C/O HARVARD BIOSCIENCE, INC.
84 OCTOBER HILL ROAD
HOLLISTON, MA 01746
X

Signatures

/s/ William Snider 12/30/2025
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Held by BroadOak Fund VI, L.P. The reporting person is the Manager of BroadOak Fund VI, L.P. The reporting person disclaims beneficial ownership of the securities held by BroadOak Fund VI, L.P except to the extent of his pecuniary interest therein, if any.
(2) Held by BroadOak Income Fund, L.P. The reporting person is the Manager of BroadOak Income Fund, L.P. The reporting person disclaims beneficial ownership of the securities held by BroadOak Income Fund, L.P except to the extent of his pecuniary interest therein, if any.
(3) The Warrants are exercisable immediately. Notwithstanding the foregoing, the Reporting Person shall not be entitled to exercise the Warrants to the extent that such exercise would cause the aggregate number of shares of common stock of the Issuer, $0.01 par value per share (the "Common Stock"), beneficially owned by the Reporting Person to exceed 19.99% of the total number of outstanding shares of Common Stock following such exercise.

Remarks:
Exhibit 24 - Power of Attorney
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
Harvard Bioscience Inc. published this content on December 30, 2025, and is solely responsible for the information contained herein. Distributed via Edgar on December 31, 2025 at 01:47 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]